Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03810339
Recruitment Status : Recruiting
First Posted : January 18, 2019
Last Update Posted : January 18, 2019
Sponsor:
Information provided by (Responsible Party):
Ruihua Xu, Sun Yat-sen University

Brief Summary:
The purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.

Condition or disease Intervention/treatment Phase
Solid Tumor Advanced Cancer Drug: Toripalimab Phase 2

Detailed Description:
Immune checkpoint inhibitor (ICI) therapy including antibodies targeting PD-1/PD-L1 or CTLA-4 has greatly advanced the cancer treatments. Recent studies have identified several predictive markers for ICI which includes microsatellite instability (MSI), PD-L1 expression and tumor mutation burden (TMB). DNA polymerase epsilon (POLE) and delta (POLD) are in charge of DNA replication as well as proofreading during DNA replication. Their germline or somatic mutations can lead to DNA repair deficiencies and carcinogenesis. The investigators has found that the POLE or POLD mutation causes an increased TMB in cancer patients and may lead to a better survival to ICI. Therefore, the purpose of this study is to evaluate the efficacy of toripalimab , a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability high (non-MSI-H) advanced solid cancers. This is a Phase II, open label, single arm study. Participants enrolled in this study received toripalimab 240mg, every 3 weeks until disease progress or intolerable toxicity. Primary endpoints is ORR and secondary endpoints are OS, PFS and safety.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open Label Study of Toripalimab, a PD-1 Antibody, in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Actual Study Start Date : January 15, 2019
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 30, 2021

Arm Intervention/treatment
Experimental: Toripalimab
Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
Drug: Toripalimab
Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity




Primary Outcome Measures :
  1. Objective Response Rates (ORR) [ Time Frame: up to 2 years ]
    the ratio of patients whose efficiency evaluation is CR or PR


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: up to 2 years ]
    defined as the period from the first dose of study treatment to loss of follow-up or death

  2. Progression free survival (PFS) [ Time Frame: up to 2 years ]
    defined as the time from the first dose of study treatment to disease progression

  3. Adverse Events (AEs) [ Time Frame: up to 2 years ]
    All treatment-related adverse events (AEs) were categorized according to the National Cancer Institute's Common Terminology Criteria for Adverse Events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must provide written informed consent to participate
  • Adult aged between 18 and 75 years old
  • Participants with Histologically- or cytologically- proven advanced solid tumors and not responding to standard therapy
  • MSS (microsatellite sability) or MSI-L (microsatellite instability-low) or pMMR status
  • Germline mutations or somatic mutations in POLE or POLD (synonymous mutation is excluded)
  • Patients refuse any conventional chemotherapy or targeted therapy
  • Patients are willing to take biopsy of tumor tissue and take blood samples before treatment (blood samples are also taken at each time of therapeutic evaluation)
  • Participants must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Lesions previously treated with radiotherapy should not be regarded as target lesions unless there is a definite progression of the lesion after radiotherapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Estimated life expectancy is greater than 3 months
  • Participants can provide more than 10 paraffin sections of tumor tissue
  • No history of radiotherapy or received non-targeted radiotherapy outside the target lesions for this study more than 4 weeks ago before the first dose of study treatment
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x (5 x in participants with liver metastasis) upper limit of normal (ULN)
  • Albumin ≥ 3 g/dL
  • Alkaline phosphatase ≤ 2.5 x ULN.
  • Serum bilirubin <1.5 mg/dL
  • Creatinine ≤ ULN.
  • Absolute neutrophil count ≥ 1.5X10E9/L
  • Platelets ≥ 100 x 10E9/L
  • Hemoglobin ≥ 90 g/L
  • For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative serum pregnancy test must be performed within 21 days of the first dose of study treatment.
  • For females: agreement to contraception during the study treatment period and for at least 28 days after the last dose of study treatment

Exclusion Criteria:

  • Patients with confirmed or suspected brain metastases
  • Patients with cancerous meningitis
  • Patients without germline mutations or somatic mutations in POLE and POLD
  • MSI-H (microsatellite instability-high) or dMMR
  • Prior treatment with PD-1 inhibitors, PD-L1 inhibitors or CTLA-4 inhibitors (or other inhibitors in T cell co-stimulatory signals or checkpoint pathways)
  • Known history or evidence of cytotoxic drug therapy, biologic drug therapy (such as monoclonal antibodies), immunotherapy (such as interleukin 2 or interferon), or other investigational drugs therapy in the 4 weeks before the first dose of study treatment
  • Known history or evidence of significant immunodeficiency (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma completely relieved can be included. Asthma that requires medical intervention cannot be included)
  • Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisolone equivalent) or other immunosuppressive medications
  • Patients with active tuberculosis. Known history of antituberculosis drugs treatment in 1 year before the first dose of study treatment
  • Administration of an anti-infection vaccine (e.g. influenza vaccine, chickenpox vaccine) in the 4 weeks before the first dose of study treatment
  • Symptomatic heart failure, coronary heart disease (CHD), myocardial infarction in the 6 months before the first dose of study treatment
  • Known allergy to JS001 or its excipients
  • Pregnant or breastfeeding females
  • Other prior malignancy active within the previous 5 years except for non-melanoma skin cancer
  • Persons without legal capacity
  • Positive test for HIV or AIDS
  • Positive test for HbsAg and HBV-DNA copy numbers (≥ 1000cps/ml)
  • Positive test for HCV
  • Any medical disorder or condition that, in the opinion of the investigator, may affect the compliance or the signing of informed consent, etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03810339


Contacts
Layout table for location contacts
Contact: Feng Wang, MD, PhD +862087342635 wangfeng@sysucc.org.cn

Locations
Layout table for location information
China, Guangdong
Cancer center of Sun Yat-sen University Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Zhi-da Lv, BS    +862087342635    lvzd@sysucc.org.cn   
Principal Investigator: Rui-hua Xu, MD, PhD         
Sub-Investigator: Feng Wang, MD, PhD         
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Layout table for investigator information
Principal Investigator: Rui-hua Xu, MD, PhD Sun Yat-sen University

Layout table for additonal information
Responsible Party: Ruihua Xu, President and Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03810339     History of Changes
Other Study ID Numbers: PPM
First Posted: January 18, 2019    Key Record Dates
Last Update Posted: January 18, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ruihua Xu, Sun Yat-sen University:
Immune checkpoint inhibitor
POLE/POLD mutation
non-MSI-H